News

CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy
CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) are pleased to announce that the European Commission has approved ...
Active Pharmaceutical Ingredients (API) Market to Amass $359.45 Billion by 2030 at CAGR 5.85% - Grand View Research, Inc.
The global active pharmaceutical ingredients market size is projected to reach USD 359.45 billion by 2030, and it is expected ...
Vifor International AG (CSL Vifor): CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI in IgA Nephropathy
European Commission converts conditional approval of FILSPARI (sparsentan) into standard marketing authorization for the treatment of IgA Nephropathy (IgAN) Decision follows positive recommendation ...